Lotan Y - Search Results

1

Editorial: Identifying novel biomarkers in bladder cancer.

Ecke TH, Lotan Y, Massfelder T. Ecke TH, et al. Among authors: lotan y. Front Oncol. 2023 Jul 4;13:1191736. doi: 10.3389/fonc.2023.1191736. eCollection 2023. Front Oncol. 2023. PMID: 37469396 Free PMC article. No abstract available.

2

MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer.

Rajendiran S, Maji S, Haddad A, Lotan Y, Nandy RR, Vishwanatha JK, Chaudhary P. Rajendiran S, et al. Among authors: lotan y. Front Oncol. 2021 Mar 19;11:628094. doi: 10.3389/fonc.2021.628094. eCollection 2021. Front Oncol. 2021. PMID: 33816263 Free PMC article.

3

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer.

Chen L, Gannavarapu BS, Desai NB, Folkert MR, Dohopolski M, Gao A, Ahn C, Cadeddu J, Bagrodia A, Woldu S, Raj GV, Roehrborn C, Lotan Y, Timmerman RD, Garant A, Hannan R. Chen L, et al. Among authors: lotan y. Front Oncol. 2022 Feb 21;12:779182. doi: 10.3389/fonc.2022.779182. eCollection 2022. Front Oncol. 2022. PMID: 35265519 Free PMC article.

4

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.

Svatek RS, Sagalowsky AI, Lotan Y. Svatek RS, et al. Among authors: lotan y. Urol Oncol. 2006 Jul-Aug;24(4):338-43. doi: 10.1016/j.urolonc.2005.11.025. Urol Oncol. 2006. PMID: 16818188

5

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.

Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Karam JA, et al. Among authors: lotan y. Lancet Oncol. 2007 Feb;8(2):128-36. doi: 10.1016/S1470-2045(07)70002-5. Lancet Oncol. 2007. PMID: 17267327

6

Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.

Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Shariat SF, et al. Among authors: lotan y. Urol Oncol. 2007 Nov-Dec;25(6):468-75. doi: 10.1016/j.urolonc.2006.09.011. Urol Oncol. 2007. PMID: 18047954

7

Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology.

Youssef RF, Schlomer BJ, Ho R, Sagalowsky AI, Ashfaq R, Lotan Y. Youssef RF, et al. Among authors: lotan y. Urol Oncol. 2012 May-Jun;30(3):273-7. doi: 10.1016/j.urolonc.2010.02.012. Epub 2010 May 6. Urol Oncol. 2012. PMID: 20451422

8

Considerations on implementing diagnostic markers into clinical decision making in bladder cancer.

Lotan Y, Shariat SF, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB. Lotan Y, et al. Urol Oncol. 2010 Jul-Aug;28(4):441-8. doi: 10.1016/j.urolonc.2009.11.004. Urol Oncol. 2010. PMID: 20610281

9

Urinary cytology for the detection of urothelial carcinoma of the bladder--a flawed adjunct to cystoscopy?

Bolenz C, West AM, Ortiz N, Kabbani W, Lotan Y. Bolenz C, et al. Among authors: lotan y. Urol Oncol. 2013 Apr;31(3):366-71. doi: 10.1016/j.urolonc.2011.01.017. Epub 2011 Mar 16. Urol Oncol. 2013. PMID: 21414815

10

Comprehensive handbook for developing a bladder cancer cystectomy database.

Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM; Bladder Cancer Think Tank; Bladder Cancer Advocacy Network. Lotan Y, et al. Urol Oncol. 2013 Aug;31(6):812-26. doi: 10.1016/j.urolonc.2011.09.004. Epub 2011 Nov 6. Urol Oncol. 2013. PMID: 22056403

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

743 results

Search Page